KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Assets: 2013-2024

Historic Other Non-Current Assets for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2024 value amounting to $18.2 million.

  • Travere Therapeutics' Other Non-Current Assets fell 40.11% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 40.11%. This contributed to the annual value of $18.2 million for FY2024, which is 70.36% up from last year.
  • Latest data reveals that Travere Therapeutics reported Other Non-Current Assets of $18.2 million as of FY2024, which was up 70.36% from $10.7 million recorded in FY2023.
  • Travere Therapeutics' 5-year Other Non-Current Assets high stood at $48.3 million for FY2022, and its period low was $7.8 million during FY2020.
  • In the last 3 years, Travere Therapeutics' Other Non-Current Assets had a median value of $18.2 million in 2024 and averaged $25.7 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first spiked by 336.73% in 2022, then plummeted by 77.95% in 2023.
  • Travere Therapeutics' Other Non-Current Assets (Yearly) stood at $7.8 million in 2020, then surged by 41.66% to $11.1 million in 2021, then spiked by 336.73% to $48.3 million in 2022, then tumbled by 77.95% to $10.7 million in 2023, then skyrocketed by 70.36% to $18.2 million in 2024.